Nature Communications (Oct 2019)
Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development
- Tiago Beites,
- Kathryn O’Brien,
- Divya Tiwari,
- Curtis A. Engelhart,
- Shaun Walters,
- Jenna Andrews,
- Hee-Jeong Yang,
- Michelle L. Sutphen,
- Danielle M. Weiner,
- Emmanuel K. Dayao,
- Matthew Zimmerman,
- Brendan Prideaux,
- Prashant V. Desai,
- Thierry Masquelin,
- Laura E. Via,
- Véronique Dartois,
- Helena I. Boshoff,
- Clifton E. Barry,
- Sabine Ehrt,
- Dirk Schnappinger
Affiliations
- Tiago Beites
- Department of Microbiology and Immunology, Weill Cornell Medical College
- Kathryn O’Brien
- Department of Microbiology and Immunology, Weill Cornell Medical College
- Divya Tiwari
- Department of Microbiology and Immunology, Weill Cornell Medical College
- Curtis A. Engelhart
- Department of Microbiology and Immunology, Weill Cornell Medical College
- Shaun Walters
- Department of Microbiology and Immunology, Weill Cornell Medical College
- Jenna Andrews
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH
- Hee-Jeong Yang
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH
- Michelle L. Sutphen
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH
- Danielle M. Weiner
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH
- Emmanuel K. Dayao
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH
- Matthew Zimmerman
- Center for Discovery and Innovation, Hackensack Meridian Health
- Brendan Prideaux
- Center for Discovery and Innovation, Hackensack Meridian Health
- Prashant V. Desai
- Lilly Research Laboratories, Eli Lilly and Company
- Thierry Masquelin
- Lilly Research Laboratories, Eli Lilly and Company
- Laura E. Via
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH
- Véronique Dartois
- Center for Discovery and Innovation, Hackensack Meridian Health
- Helena I. Boshoff
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH
- Clifton E. Barry
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH
- Sabine Ehrt
- Department of Microbiology and Immunology, Weill Cornell Medical College
- Dirk Schnappinger
- Department of Microbiology and Immunology, Weill Cornell Medical College
- DOI
- https://doi.org/10.1038/s41467-019-12956-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
New tuberculosis therapies, targeting respiratory chain components of Mycobacterium tuberculosis, are under development. Here the authors show that, contrary to common belief, some of these components are not essential for pathogen viability and/or virulence in animal models of infection.
